Should pre-transplant MRD be used to guide treatment in AML?

During the EHA2021 Virtual Congress, the AML Hub spoke with Charles Craddock, Queen Elizabeth Hospital Birmingham, Birmingham, UK. We asked, Should pre-transplant minimal residual disease (MRD) be used to guide treatment in acute myeloid leukemia (AML)?

Craddock begins by outlining the reasons for the increased use of allogeneic transplant and reviews data that discuss the exclusion criteria and benefits of transplant. He goes on to discuss how patient outcomes could be improved and the importance of post-transplant maintenance. Finally, he highlights the need to generate prospective data, referring to the ongoing studies COSI and AMADEUS.

Hosted on Acast. See acast.com/privacy for more information.